Targeting ketone body metabolism to treat fatty liver disease
Journal of Pharmacy & Pharmaceutical Sciences · 30.09.2024 · 27
DOI: 10.3389/jpps.2024.13375 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, online erschienen am 30.09.2024. Verfasst von Sora Kwon und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Ottawa Heart Institute, Ottawa, ON, Canada. Hauptthemen laut MEDLINE: Ketone Bodies, Fatty Liver. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic disorder marked by excessive accumulation of lipids within the liver. If untreated, this condition can progress to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and ultimately, hepatocellular carcinoma (HCC). Given the liver’s pivotal role in glucose and fatty acid metabolism, disruptions in these processes are commonly observed in MASLD. Ketone bodies, crucial energy metabolites primarily produced in the liver, are also closely related to the progression of MASLD. Recent studies have demonstrated that disrupted ketogenesis not only accompanies MASLD, but may also play a causal role in its development and progression. Moreover, activation of the ketogenic pathway has been suggested as a promising strategy for reducing excessive hepatic fat accumulation. This review focuses on the regulation of ketogenesis in MASLD, emphasizing the significance of dietary and pharmacological interventions as potential therapeutic approaches to treat fatty liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Ottawa Heart Institute, Ottawa, ON, Canada.
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
- Translational and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Zitieren
APA
Kwon, S., Jeyaratnam, R., & Kim, K. H. (2024). Targeting ketone body metabolism to treat fatty liver disease. Journal of Pharmacy & Pharmaceutical Sciences, 27. https://doi.org/10.3389/jpps.2024.13375
Vancouver
Kwon S, Jeyaratnam R, Kim KH. Targeting ketone body metabolism to treat fatty liver disease. Journal of Pharmacy & Pharmaceutical Sciences. 2024;27. doi:10.3389/jpps.2024.13375
BibTeX
@article{Kwon2024,
author = {Kwon, Sora and Jeyaratnam, Reshani and Kim, Kyoung-Han},
title = {Targeting ketone body metabolism to treat fatty liver disease},
journal = {Journal of Pharmacy & Pharmaceutical Sciences},
year = {2024},
volume = {27},
doi = {10.3389/jpps.2024.13375}
}
EUVIMED